



No. THSTI/S&P/RFP/01/26-27

Dated:16.10.2026

CORRIGENDUM

Ref.: RFP No. THSTI/S&P/RFP/01/26-27 dt. 09th October 26

GeM Bid Number: GEM/2026/B/8139733 dt. 09th October 26

Name of Work/Services: Development of novel monoclonal antibody: Pharmacokinetics, Safety pharmacology and Toxicology study for investigational new drug.

The following amendment is hereby incorporated into the RFP document:

Under Para 5(b) – Role of Bidder, the following clause is added:

“In accordance with the principle of 3Rs (Replace, Reduce, Refine), the bidder may take measurements necessary for safety pharmacology studies as described in the scope, from animals which are being employed for the GLP-Toxicology study, without influencing the results of the latter study in any manner.”

Bidders are requested to take note of the above amendment while preparing and submitting their bids.

All other terms and conditions of the RFP document shall remain unchanged.

**Sd/-
Administrative Officer (S&P)**